Connective tissue diseases: The conundrum of B cell depletion in SLE.
Level V
Where this comes from
- Record sourced from PubMed, PMID 19491910.
- Also identified by DOI 10.1038/nrrheum.2009.100.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two consecutive trials of rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, have threatened the future of B-cell-targeted therapy for systemic lupus erythematosus (SLE). While rumors of the demise of this approach might be greatly exaggerated, the outcomes of these studies should force academics and the pharmaceutical industry back to the drawing board.
Medical subject headings
- Antibodies, Monoclonal
- B-Lymphocytes
- Immunologic Factors
- Lupus Erythematosus, Systemic